Cholera Vaccine Confers Durable Protection

Cumulative efficacy against severe cholera was 65% over 5 years.

Studies have confirmed that a bivalent killed whole-cell oral cholera vaccine (Shanchol; Shantha Biotechnics, Hyderabad, India) can provide protection for up to 3 years (NEJM JW Infect Dis Oct 21 2009). To examine longer-term efficacy, researchers (1 of whom is a Shantha employee) conducted a double-blind, cluster-randomized, placebo-controlled trial in a slum in Kolkata, India, where cholera is endemic.

More than 65,000 nonpregnant residents aged ≥1 year received two doses of vaccine or placebo (heat-killed Escherichia coli K12) 14 days apart. The vaccine, prequalified by WHO in 2011, contains inactivated Vibrio cholerae O1 and V. cholerae O139. The primary endpoint was cases of culture-confirmed cholera severe enough to require treatment a…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Cholera Vaccine Confers Durable Protection

Topics

Reviewing Author